Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6826788 | 0.82 | KDM4E (0.36) | DRD2DRD3 | |
| SCHEMBL4397316 | 0.81 | HRH4 (0.40) | DRD2DRD3 | |
| SCHEMBL392268 | 0.80 | DRD2 (0.66) | DRD2DRD3 | |
| SCHEMBL5162498 | 0.80 | CETP (0.46) | DRD2DRD3 | |
| SCHEMBL12959304 | 0.79 | DRD2 (0.49) | DRD2DRD3 | |
| SCHEMBL5170798 | 0.79 | DRD2 (0.34) | DRD2DRD3 | |
| SCHEMBL6600239 | 0.76 | DRD2 (0.66) | DRD2DRD3 | |
| SCHEMBL2232549 | 0.76 | DRD2 (0.67) | DRD2DRD3 | |
| SCHEMBL392228 | 0.71 | DRD2 (0.56) | DRD2DRD3 | |
| SCHEMBL388042 | 0.70 | DRD2 (0.45) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817037-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULAIONT OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006058753-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULAIONT OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-06-08 | — | — | WO | disclosed |
| CN-1144791-C | Triazole compounds and use thereof as dopamine-D3-ligands | BASF | 2004-04-07 | — | — | CN | disclosed |
| CN-1267286-A | 2-{3-[4-(2-t-butyl-6-trifluoromethylpyridin-4-yl) piperazin-1-yl] propylmercapto} pyrimidin-4-ol-fumarate | BASF AG (DE) | 2000-09-20 | — | — | CN | disclosed |